Anebulo Pharmaceuticals, Inc. - Common Stock (ANEB)

Let's delve into the US markets on Friday and uncover the stocks that are experiencing notable gaps in today's session. Below, you'll find the gap up and gap down stocks.

The US market session of Friday has yet to be opened, let's have a look at the top gainers and losers in the pre-market session today.

H.C.

Discover the stocks with unexpected trading volume in today's session on the US markets.

ANEB stock results show that Anebulo Pharmaceuticals beat analyst estimates for earnings per share the third quarter of 2024.

Substance use disorder-focused biopharmaceutical company Anebulo Pharmaceuticals, Inc. (NASDAQ: ANEB) reported on Tuesday second quarter financial results for the three months ended Dec. 31, 2023, The company's primary focus is on developing therapy for acute cannabinoid intoxication (ACI).Total operating expenses in the second quarter of fiscal 2024 were $2.8 million compared with $3.8 million in the same period in fiscal 2023.Net loss in the second quarter of fiscal 2024 was $2.7 million, or $(0.11) per share, compared with a net loss of $3.8 million, or $(0.15) per share, in the second quarter of fiscal 2023.

Gainers SciSparc Ltd. (NASDAQ: SPRC) shares climbed 146.2% to $6.97. Aegis Capital Corp. acted as exclusive placement agent on a $5.0 million private placement for SciSparc.

Anebulo Pharmaceuticals, Inc. (NASDAQ: ANEB) announced positive feedback from the United States Food and Drug Administration following a type B meeting in July.